In vitro modulation of the glucocorticoid receptor by antidepressants

Stress

Volumn 11, Issue 6, 2008, Pages 411-424

  Carvalho, Livia A ^a   Pariante, Carmine M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Corticosterone; Cortisol; Dexamethasone; Major depression; Mineralocorticoid receptor; Multidrug resistance P glycoprotein

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DESIPRAMINE; DEXAMETHASONE; FLUOXETINE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; IMIPRAMINE; MAPROTILINE; MESSENGER RNA; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; PARGYLINE; PAROXETINE; PHENELZINE; PREDNISOLONE; REBOXETINE; RESERPINE; TIANEPTINE; TRAZODONE; VASOPRESSIN; VENLAFAXINE;

DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG TARGETING; HORMONE RESISTANCE; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; IN VITRO STUDY; MAJOR DEPRESSION; MOLECULAR MECHANICS; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; REVIEW; TISSUE LEVEL;

ANIMALS; ANTIDEPRESSIVE AGENTS; CELLS, CULTURED; DEPRESSIVE DISORDER, MAJOR; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PITUITARY-ADRENAL SYSTEM; RECEPTORS, GLUCOCORTICOID;

EID: 57349143222     PISSN: 10253890     EISSN: 16078888     Source Type: Journal    
DOI: 10.1080/10253890701850759     Document Type: Review

References (125)

1. Antoni FA. 1993. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 14:76-122.
2. Augustyn M, Otczyk M, Budziszewska B, Jagla G, Nowak W, Basta-Kaim A, et al. 2005. Effects of some new antidepressant drugs on the glucocorticoid receptor-mediated gene transcription in fibroblast cells. Pharmacol Rep 57:766-773.
3. Axelson DA, Doraiswamy PM, Boyko OB, Rodrigo EP, McDonald WM, Ritchie JC, et al. 1992. In vivo assessment of pituitary volume with magnetic resonance imaging and systematic stereology: Relationship to dexamethasone suppression test results in patients. Psychiatr Res 44:63-70.
4. Barden N. 1996. Modulation of glucocorticoid receptor gene expression by antidepressant drugs. Pharmacopsychiatry 29:12-22.
5. Basta-Kaim A, Budziszewska B, Jaworska-Feil L, Tetich M, Kubera M, Leskiewicz M, et al. 2006. Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases. Neuropsychopharmacology 31:853-865.
6. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. 2001. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmcol 21:516-521.
7. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, et al. 2004. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 36:1319-1325.
8. Bouron A, Chatton JY. 1999. Acute application of the tricyclic antidepressant desipramine presynaptically stimulates the exocytosis of glutamate in the hippocampus. Neuroscience 90:729-736.
9. Bouwer C, Claassen J, Dinan TG, Nemeroff CB. 2000. Prednisone augmentation in treatment-resistant depression with fatigue and hypocortisolaemia: A case series. Depress Anxiety 12:44-50.
10. Budziszewska B, Jaworska-Feil L, Kajta M, Lason W. 2000. Antidepressant drugs inhibit glucocorticoid receptor-mediated gene transcription - a possible mechanism. Br J Pharmacol 130:1385-1393.
11. Budziszewska B, Basta-Kaim A, Kubera M, Jaworska L, Leskiewicz M, Tetich M, et al. 2005. Effect of lipopolysaccharide and antidepressant drugs on glucocorticoid receptor-mediated gene transcription. Pharmacol Rep 57:540-544.
12. Burnstein KL, Jewell CM, Sar M, Cidlowski JA. 1994. Intragenic sequences of the human glucocorticoid receptor complementary DNA mediate hormone-inducible receptor messenger RNA down-regulation through multiple mechanisms. Mol Endocrinol 8:1764-1773.
13. Cai W, Khaoustov VI, Xie Q, Pan T, Le W, Yoffe B. 2005. Interferon-alpha-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression. J Hepatol 42:880-887.
14. Calfa G, Kademian S, Ceschin D, Vega G, Rabinovich GA, Volosin M. 2003. Characterization and functional significance of glucocorticoid receptors in patients with major depression: Modulation by antidepressant treatment. Psychoneuroendocrinology 28:687-701.
15. Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskett RF, et al. 1981. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry 38:15-22.
16. Cidlowski JA, Bellingham DL, Powell-Oliver FE, Lubahn DB, Sar M. 1990. Novel antipeptide antibodies to the human glucocorticoid receptor: Recognition of multiple receptor forms in vitro and distinct localization of cytoplasmic and nuclear receptors. Mol Endocrinol 4:1427-1437.
17. Cooney JM, Dinan TG. 1996. Preservation of hypothalamic-pituitary-adrenal axis fast-feedback responses in depression. Acta Psychiatr Scand 94:449-453.
18. DeBattista C, Posener JA, Kalehzan BM, Schatzberg AF. 2000. Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: A double-blind, placebo-controlled study. Am J Psychiatry 157:1334-1337.
19. Dinan TG, Lavelle E, Cooney J, Burnett F, Scott L, Dash A, et al. 1997. Dexamethasone augmentation in treatment-resistant depression. Acta Psychiatr Scand 95:58-61.
20. Duman RS, Nakagawa S, Malberg J. 2001. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology 25:836-844.
21. Dumser T, Barocka A, Schubert E. 1998. Weight of adrenal glands may be increased in persons who commit suicide. Am J Forensic Med Pathol 19:72-76.
22. Eickelberg O, Roth M, Lorx R, Bruce V, Rudiger J, Johnson M, et al. 1999. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 274:1005-1010.
23. Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M. 2000. Multiple actions of steroid hormones - a focus on rapid, nongenomic effects. Pharmacol Rev 52:513-556.
24. Fitzgerald P, O'Brien SM, Scully P, Rijkers K, Scott LV, Dinan TG. 2006. Cutaneous glucocorticoid receptor sensitivity and proinflammatory cytokine levels in antidepressant-resistant depression. Psychol Med 36:37-43.
25. Funato H, Kobayashi A, Watanabe Y. 2006. Differential effects of antidepressants on dexamethasone-induced nuclear translocation and expression of glucocorticoid receptor. Brain Res 1117:125-134.
26. Gold PW, Chrousos GP. 2002. Organization of the stress system and its dysregulation in melancholic and atypical depression: High vs low CRH/NE states. Mol Psychiatry 7:254-275.
27. Gold PW, Goodwin FK, Chrousos GP. 1988. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (1). N Engl J Med 319:348-353.
28. Gormley GJ, Lowy MT, Reder AT, Hospelhorn VD, Antel JP, Meltzer HY. 1985. Glucocorticoid receptors in depression: Relationship to the dexamethasone suppression test. Am J Psychiatry 142:1278-1284.
29. Heiske A, Jesberg J, Krieg JC, Vedder H. 2003. Differential effects of antidepressants on glucocorticoid receptors in human primary blood cells and human monocytic u-937 cells. Neuropsychopharmacology 28:807-817.
30. Herr AS, Tsolakidou AF, Yassouridis A, Holsboer F, Rein T. 2003. Antidepressants differentially influence the transcriptional activity of the glucocorticoid receptor in vitro. Neuroendocrinology 78:12-22.
31. Hery M, Semont A, Fache MP, Faudon M, Hery F. 2000. The effects of serotonin on glucocorticoid receptor binding in rat raphe nuclei and hippocampal cells in culture. J Neurochem 74:406-413.
32. Heuser I, Yassouridis A, Holsboer F. 1994. The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders. J Psychiatr Res 28:341-356.
33. Heuser IJ, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Dettling M, et al. 1996. Pituitary-adrenal system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry 153:93-99.
34. Holsboer F. 2000. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23:477-501.
35. Ising M, Lauer CJ, Holsboer F, Modell S. 2005. The Munich vulnerability study on affective disorders: Premorbid neuroendocrine profile of affected high-risk probands. J Psychiatr Res 39:21-28.
36. Juruena MF, Cleare AJ, Pariante CM. 2004. The hypothalamic-pituitary- adrenal axis, glucocorticoid receptor function and relevance to depression. Rev Bras Psiquiatr 26:189-201.
37. Juruena MF, Cleare AJ, Papadopoulos AS, Poon L, Lightman S, Pariante CM. 2006. Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology (Berl) 189:225-235.
38. Karst H, Berger S, Turiault M, Tronche F, Schutz G, Joels M. 2005. Mineralocorticoid receptors are indispensable for nongenomic modulation of hippocampal glutamate transmission by corticosterone. Proc Natl Acad Sci USA 102:19204-19207.
39. de Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. 1998. Brain corticosteroid receptor balance in health and disease. Endocr Rev 19:269-301.
40. de Kloet ER, Derijk RH, Meijer OC. 2007. Therapy insight: Is there an imbalanced response of mineralocorticoid and glucocorticoid receptors in depression? Nat Clin Pract Endocrinol Metab 3:168-179.
41. Kunugi H, Ida I, Owashi T, Kimura M, Inoue Y, Nakagawa S, et al. 2006. Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: A multicenter study. Neuropsychopharmacology 31:212-220.
42. Lai M, McCormick JA, Chapman KE, Kelly PAT, Seckl JR, Yau JLW. 2003. Differential regulation of corticosteroid receptors by monoamine neurotransmitters and antidepressant drugs in primary hippocampal culture. Neuroscience 118:975-984.
43. Lauer CJ, Schreiber W, Modell S, Holsboer F, Krieg JC. 1998. The Munich vulnerability study on affective disorders: Overview of the cross-sectional observations at index investigation. J Psychiatr Res 32:393-401.
44. Levitan RD, Vaccarino FJ, Brown GM, Kennedy SH. 2002. Low-dose dexamethasone challenge in women with atypical major depression: Pilot study. J Psychiatry Neurosci 27:47-51.
45. Linkowski P, Mendlewicz J, Kerkhofs M, Leclercq R, Golstein J, Brasseur M, et al. 1987. 24-hour profiles of adrenocorticotropin, cortisol, and growth hormone in major depressive illness: Effect of antidepressant treatment. J Clin Endocrinol Metab 65:141-152.
46. Lowy MT. 1990. Reserpine-induced decrease in type I and II corticosteroid receptors in neuronal and lymphoid tissues of adrenalectomized rats. Neuroendocrinology 51:190-196.
47. Lowy MT, Reder AT, Antel JP, Meltzer HY. 1984. Glucocorticoid resistance in depression: The dexamethasone suppression test and lymphocyte sensitivity to dexamethasone. Am J Psychiatry 141:1365-1370.
48. Lowy MT, Reder AT, Gormley GJ, Meltzer HY. 1988. Comparison of in vivo and in vitro glucocorticoid sensitivity in depression: relationship to the dexamethasone suppression test. Biol Psychiatry 24:619-630.
49. Lu NZ, Cidlowski JA. 2005. Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol Cell 18:331-342.
50. Maddock C, Pariante CM. 2001. How does stress affect you? An overview of stress, immunity, depression and disease. Epidemiol Psichiatr Soc 10:153-162.
51. Maddock C, Baita A, Orru MG, Sitzia R, Costa A, Muntoni E, et al. 2004. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: A prospective case series and a discussion of biological mechanisms. J Psychopharmacol 18:41-46.
52. Maddock C, Landau S, Barry K, Maulayah P, Hotopf M, Cleare AJ, et al. 2005. Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response. Mol Psychiatry 10:332-333.
53. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. 1995. The nuclear receptor superfamily: The second decade. Cell 83:835-839.
54. Manier DH, Shelton RC, Ellis TC, Peterson CS, Eiring A, Sulser F. 2000. Human fibroblasts as a relevant model to study signal transduction in affective disorders. J Affect Disord 61:51-58.
55. McEwen BS, Biron CA, Brunson KW, Bulloch K, Chambers WH, Dhabhar FS, et al. 1997. The role of adrenocorticoids as modulators of immune function in health and disease: Neural, endocrine and immune interactions. Brain Res Brain Res Rev 23:79-133.
56. McQuade R, Young AH. 2000. Future therapeutic targets in mood disorders: The glucocorticoid receptor. Br J Psychiatry 177:390-395.
57. Merali Z, Du L, Hrdina P, Palkovits M, Faludi G, Poulter MO, et al. 2004. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci 24:1478-1485.
58. Merry S, Hamilton TG, Flanigan P, Freshney RI, Kaye SB. 1991. Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine. Eur J Cancer 27:31-34.
59. Miller AH, Pariante CM, Pearce BD. 1999. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv Exp Med Biol 461:107-116.
60. Miller AH, Vogt GJ, Pearce BD. 2002. The phosphodiesterase type 4 inhibitor, rolipram, enhances glucocorticoid receptor function. Neuropsychopharmacology 27:939-948.
61. Modell S, Lauer CJ, Schreiber W, Huber J, Krieg JC, Holsboer F. 1998. Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology 18:253-262.
62. Murphy BE. 1991. Steroids and depression. J Steroid Biochem Mol Biol 38:537-559.
63. Nalepa I, Vetulani J. 1991. Involvement of protein kinase C in the mechanism of in vitro effects of imipramine on generation of second messengers by noradrenaline in cerebral cortical slices of the rat. Neuroscience 44:585-590.
64. Nemeroff CB. 1996. The corticotropin-releasing factor (CRF) hypothesis of depression: New findings and new directions. Mol Psychiatry 1:336-342.
65. Oakley RH, Sar M, Cidlowski JA. 1996. The human glucocorticoid receptor beta isoform expression, biochemical properties, and putative function. J Biol Chem 271:9550-9559.
66. Okugawa G, Omori K, Suzukawa J, Fujiseki Y, Kinoshita T, Inagaki C. 1999. Long-term treatment with antidepressants increases glucocorticoid receptor binding and gene expression in cultured rat hippocampal neurones. J Neuroendocrinol 11:887-895.
67. Okuyama-Tamura M, Mikuni M, Kojima I. 2003. Modulation of the human glucocorticoid receptor function by antidepressive compounds. Neurosci Lett 342:206-210.
68. Pariante CM. 2003. Depression, stress and the adrenal axis. J Neuroendocrinol 15:811-812.
69. Pariante CM. 2004. Glucocorticoid receptor function in vitro in patients with major depression. Stress 7:209-219.
70. Pariante CM. 2006. The glucocorticoid receptor: Part of the solution or part of the problem? J Psychopharmacol 20:79-84.
71. Pariante CM, Miller AH. 2001. Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. Biol Psychiatry 49:391-404.
72. Pariante CM, Landau S, Carpiniello B. 2002a. Interferon alpha-induced adverse effects in patients with a psychiatric diagnosis. N Engl J Med 347:148-149.
73. Pariante CM, Kim RB, Makoff A, Kerwin RW. 2003b. Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br J Pharmacol 139:1111-1118.
74. Pariante CM, Dazzan P, Danese A, Morgan KD, Brudaglio F, Morgan C, et al. 2005. Increased pituitary volume in antipsychotic-free and antipsychotic- treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology 30:1923-1931.
75. Pariante CM, Hye A, Williamson R, Makoff A, Lovestone S, Kerwin RW. 2003a. The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology 28:1553-1561.
76. Pariante CM, Makoff A, Lovestone S, Feroli S, Heyden A, Miller AH, et al. 2001a. Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br J Pharmacol 134:1335-1343.
77. Pariante CM, Papadopoulos AS, Poon L, Checkley SA, English J, Kerwin RW, et al. 2002b. A novel prednisolone suppression test for the hypothalamic- pituitary-adrenal axis. Biol Psychiatry 51:922-930.
78. Pariante CM, Papadopoulos AS, Poon L, Cleare AJ, Checkley SA, English J, et al. 2004a. Four days of citalopram increase suppression of cortisol secretion by prednisolone in healthy volunteers. Psychopharmacology (Berl) 177:200-206.
79. Pariante CM, Pearce BD, Pisell TL, Owens MJ, Miller AH. 1997. Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol Pharmacol 52:571-581.
80. Pariante CM, Pearce BD, Pisell TL, Sanchez CI, Po C, Su C, et al. 1999. The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function. Endocrinology 140:4359-4366.
81. Pariante CM, Pearce BD, Pisell TL, Su C, Miller AH. 2001b. The steroid receptor antagonists RU40555 and RU486 activate glucocorticoid receptor translocation and are not excreted by the steroid hormones transporter in L929 cells. J Endocrinol 169:309-320.
82. Pariante CM, Thomas SA, Lovestone S, Makoff A, Kerwin RW. 2004b. Do antidepressants regulate how cortisol affects the brain?. 2003 Curt Richter Award Paper Psychoneuroendocrinology 29:423-447.
83. Pariante CM, Vassilopoulou K, Velakoulis D, Phillips L, Soulsby B, Wood SJ, et al. 2004c. Pituitary volume in psychosis. Br J Psychiatry 185:5-10.
84. Peiffer A, Veilleux S, Barden N. 1991. Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain. Psychoneuroendocrinology 16:505-515.
85. Pepin MC, Beaulieu S, Barden N. 1989. Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Brain Res Mol Brain Res 6:77-83.
86. Pepin MC, Govindan MV, Barden N. 1992a. Increased glucocorticoid receptor gene promoter activity after antidepressant treatment. Mol Pharmacol 41:1016-1022.
87. Pepin MC, Pothier F, Barden N. 1992b. Antidepressant drug action in a transgenic mouse model of the endocrine changes seen in depression. Mol Pharmacol 42:991-995.
88. Pridmore S. 1999. Rapid transcranial magnetic stimulation and normalization of the dexamethasone suppression test. Psychiatry Clin Neurosci 53:33-37.
89. Prima V, Depoix C, Masselot B, Formstecher P, Lefebvre P. 2000. Alteration of the glucocorticoid receptor subcellular localization by non steroidal compounds. J Steroid Biochem Mol Biol 72:1-12.
90. Raison CL, Miller AH. 2003. When not enough is too much: The role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 160:1554-1565.
91. Rangarajan PN, Umesono K, Evans RM. 1992. Modulation of glucocorticoid receptor function by protein kinase A. Mol Endocrinol 6:1451-1457.
92. Rasenick MM, Chaney KA, Chen J. 1996. G protein-mediated signal transduction as a target of antidepressant and antibipolar drug action: Evidence from model systems. J Clin Psychiatry 57(Suppl 13):49-55.
93. Reid PD, Pridmore S. 1999. Dexamethasone suppression test reversal in rapid transcranial magnetic stimulation-treated depression. Aust N Z J Psychiatry 33:274-277.
94. van Rossum EF, Binder EB, Majer M, Koper JW, Ising M, Modell S, et al. 2006. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry 59:681-688.
95. Rubin R, Dinan TJ, Scott LV. 2001. The neuroendocrinology of affective disorders. In: Pfaff D, Arnold AP, Etgen AM, Fahrbach SE, Moss PL, Rubin RT, editors. Hormones, brain and behaviour. New York, NY: Academic Press. p 467-514.
96. Rupprecht R, Kornhuber J, Wodarz N, Lugauer J, Gobel C, Riederer P, et al. 1991. Lymphocyte glucocorticoid receptor binding during depression and after clinical recovery. J Affect Disord 22:31-35.
97. Sanchez ER, Hu JL, Zhong S, Shen P, Greene MJ, Housley PR. 1994. Potentiation of glucocorticoid receptor-mediated gene expression by heat and chemical shock. Mol Endocrinol 8:408-421.
98. Schaaf MJM, Cidlowski JA. 2002. Molecular mechanisms of glucocorticoid action and resistance. J Steroid Biochem Mol Biol 83:37-48.
99. Schmidt TJ, Meyer AS. 1994. Autoregulation of corticosteroid receptors. How, when, where, and why? Receptor 4:229-257.
100. 2+-regulatedmyosin phosphorylation by fluoxetine and iprindole. Eur J Pharmacol 121:65-71.
101. Spencer RL, Miller AH, Stein M, McEwen BS. 1991. Corticosterone regulation of type I and type II adrenal steroid receptors in brain, pituitary, and immune tissue. Brain Res 549:236-246.
102. Stewart JW, Quitkin FM, McGrath PJ, Klein DF. 2005. Defining the boundaries of atypical depression: Evidence from the HPA axis supports course of illness distinctions. J Affect Disord 86:161-167.
103. Szabo D, Szabo G, Jr., Ocsovszki I, Aszalos A, Molnar J. 1999. Antipsychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo. Cancer Lett 139:115-119.
104. Tasker JG, Di S, Malcher-Lopes R. 2006. Minireview: Rapid glucocorticoid signaling via membrane-associated receptors. Endocrinology 147:5549-5556.
105. Varga A, Nugel H, Baehr R, Marx U, Hever A, Nacsa J, et al. 1996. Reversal of multidrug resistance by amitriptyline in vitro. Anticancer Res 16:209-211.
106. Vedder H, Bening-Abu-Shach U, Lanquillon S, Krieg JC. 1999. Regulation of glucocorticoid receptor-mRNA in human blood cells by amitriptyline and dexamethasone. J Psychiatr Res 33:303-308.
107. Wang X, Wu H, Miller AH. 2004. Interleukin 1alpha (IL-1alpha) induced activation of p38 mitogen-activated protein kinase inhibits glucocorticoid receptor function. Mol Psychiatry 9:65-75.
108. Wassef A, Smith EM, Rose RM, Gardner R, Nguyen H, Meyer WJ. 1990. Mononuclear leukocyte glucocorticoid receptor binding characteristics and down-regulation in major depression. Psychoneuroendocrinology 15:59-68.
109. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. 2003. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305:197-204.
110. Whalley LJ, Borthwick N, Copolov D, Dick H, Christie JE, Fink G. 1986. Glucocorticoid receptors and depression. Br Med J (Clin Res Ed) 292:859-861.
111. Wodarz N, Rupprecht R, Kornhuber J, Schmitz B, Wild K, Braner HU, et al. 1991. Normal lymphocyte responsiveness to lectins but impaired sensitivity to in vitro glucocorticoids in major depression. J Affect Disord 22:241-248.
112. Wodarz N, Rupprecht R, Kornhuber J, Schmitz B, Wild K, Riederer P. 1992. Cell-mediated immunity and its glucocorticoid-sensitivity after clinical recovery from severe major depressive disorder. J Affect Disord 25:31-38.
113. Yau JL, Noble J, Thomas S, Kerwin R, Morgan PE, Lightman S, et al. 2007. The antidepressant desipramine requires the ABCB1 (Mdr1)-type P-glycoprotein to upregulate the glucocorticoid receptor in mice. Neuropsychopharmacology.
114. Yehuda R. 2001. Biology of posttraumatic stress disorder. J Clin Psychiatry 64(Suppl 17):41-46.
115. Yehuda R, Boisoneau D, Mason JW, Giller EL. 1993. Glucocorticoid receptor number and cortisol excretion in mood, anxiety, and psychotic disorders. Biol Psychiatry 34:18-25.
116. Yehuda R, Golier JA, Yang RK, Tischler L. 2004. Enhanced sensitivity to glucocorticoids in peripheral mononuclear leukocytes in posttraumatic stress disorder. Biol Psychiatry 55:1110-1116.
117. Yehuda R, Halligan SL, Grossman R, Golier JA, Wong C. 2002. The cortisol and glucocorticoid receptor response to low dose dexamethasone administration in aging combat veterans and holocaust survivors with and without posttraumatic stress disorder. Biol Psychiatry 52:393-403.
118. Yehuda R, Yang RK, Golier JA, Grossman RA, Bierer LM, Tischler L. 2006. Effect of sertraline on glucocorticoid sensitivity of mononuclear leukocytes in post-traumatic stress disorder. Neuropsychopharmacology 31:189-196.
119. Young EA, Haskett RF, Murphy-Weinberg V, Watson SJ, Akil H. 1991. Loss of glucocorticoid fast feedback in depression. Arch Gen Psychiatry 48:693-699.
120. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H. 2003. Mineralocorticoid receptor function in major depression. Arch Gen Psychiatry 60:24-28.
121. Young AH, Gallagher P, Watson S, Del Estal D, Owen BM, Nicol FI. 2004. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 29:1538-1545.
122. Yuuki N, Ida I, Oshima A, Kumano H, Takahashi K, Fukuda M, et al. 2005. HPA axis normalization, estimated by DEX/CRH test, but less alteration on cerebral glucose metabolism in depressed patients receiving ECT after medication treatment failures. Acta Psychiatr Scand 112:257-265.
123. Zobel AW, Yassouridis A, Frieboes RM, Holsboer F. 1999. Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatry 156:949-951.
124. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M. 2001. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. A prospective study. J Psychiatr Res 35:83-94.
125. Zwanzger P, Baghai TC, Padberg F, Ella R, Minov C, Mikhaiel P, et al. 2003. The combined dexamethasone-CRH test before and after repetitive transcranial magnetic stimulation (rTMS) in major depression. Psychoneuroendocrinology 28:376-385.